This is somewhat in contrast to previous results, which have shown that during IFN-α therapy, NK-cell cytotoxicity against K562 cells and autologous CML cells is increased [34], [35]. Here, IFNA1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.